Logo for Merus N.V.

Merus Investor Relations Material

Latest events

Logo for Merus N.V.

Investor Update

Merus
Logo for Merus

Q4 2024

27 Feb, 2025
Logo for Merus

Investor Update

7 Dec, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies

Latest reports from Merus N.V.

Access all reports
Merus N.V. is a clinical-stage immuno-oncology company focused on developing innovative bispecific antibody therapeutics. The company specializes in creating full-length human multispecific antibodies known as Biclonics and Triclonics, which are designed to engage multiple targets, offering new approaches to treat various cancers. Merus has a broad pipeline, including candidates in different stages of clinical trials targeting solid tumors and hematologic malignancies. The company is headquartered in Utrecht, Netherlands, and its shares are listed on the Nasdaq.